Amir Mortazavi

4.8k total citations
108 papers, 1.7k citations indexed

About

Amir Mortazavi is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amir Mortazavi has authored 108 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Surgery, 52 papers in Oncology and 44 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amir Mortazavi's work include Bladder and Urothelial Cancer Treatments (48 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Renal cell carcinoma treatment (22 papers). Amir Mortazavi is often cited by papers focused on Bladder and Urothelial Cancer Treatments (48 papers), Cancer Immunotherapy and Biomarkers (29 papers) and Renal cell carcinoma treatment (22 papers). Amir Mortazavi collaborates with scholars based in United States, Canada and Spain. Amir Mortazavi's co-authors include Steven K. Clinton, Kenneth M. Riedl, Jennifer M. Thomas‐Ahner, Christopher R. Lucas, Debra L. Zynger, Sumanta K. Pal, Steven J. Schwartz, Lai Wei, Michael A. Freitas and Guru Sonpavde and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Amir Mortazavi

104 papers receiving 1.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Amir Mortazavi	658	621	573	455	190	108	1.7k
Christos Vaklavas	525 0.8×	574 0.9×	287 0.5×	278 0.6×	167 0.9×	55	1.4k
Jianqing Lin	849 1.3×	491 0.8×	298 0.5×	515 1.1×	103 0.5×	62	1.7k
Mireille Mousseau	651 1.0×	663 1.1×	241 0.4×	635 1.4×	174 0.9×	40	1.5k
Mingxin Che	703 1.1×	582 0.9×	255 0.4×	457 1.0×	91 0.5×	36	1.9k
Kazuki Sudo	724 1.1×	642 1.0×	653 1.1×	647 1.4×	132 0.7×	120	1.9k
Chueh‐Chuan Yen	541 0.8×	1.2k 1.9×	821 1.4×	708 1.6×	120 0.6×	57	2.3k
Yuichiro Takeda	387 0.6×	780 1.3×	351 0.6×	629 1.4×	87 0.5×	123	1.6k
Shigefumi Yoshino	652 1.0×	836 1.3×	353 0.6×	349 0.8×	568 3.0×	114	1.9k
Lisa M. Schumaker	912 1.4×	702 1.1×	481 0.8×	264 0.6×	121 0.6×	44	2.4k
Sung Sook Lee	550 0.8×	1.2k 1.9×	344 0.6×	1.1k 2.5×	128 0.7×	77	2.1k

Countries citing papers authored by Amir Mortazavi

Since Specialization

Citations

This map shows the geographic impact of Amir Mortazavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir Mortazavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir Mortazavi more than expected).

Fields of papers citing papers by Amir Mortazavi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amir Mortazavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir Mortazavi. The network helps show where Amir Mortazavi may publish in the future.

Co-authorship network of co-authors of Amir Mortazavi

This figure shows the co-authorship network connecting the top 25 collaborators of Amir Mortazavi. A scholar is included among the top collaborators of Amir Mortazavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amir Mortazavi. Amir Mortazavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chowdhury, Sayan Mullick, Feng Hong, Christian Rolfo, et al.. (2025). CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications. Biology. 14(2). 214–214.

Simon, Nicholas I., Stephanie Berg, Alan Tan, et al.. (2025). Preferred treatment regimens for rare genitourinary (GU) malignancies.. Journal of Clinical Oncology. 43(5_suppl). 780–780.

Xu, Menglin, Elshad Hasanov, Katharine A. Collier, et al.. (2024). Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). 5057–5057. 1 indexed citations

Pan, Elizabeth, Andrew Elliott, Shankar Siva, et al.. (2024). Characterization of FOLH1 Expression in Renal Cell Carcinoma. Cancers. 16(10). 1855–1855. 1 indexed citations

Grivas, Petros, Srikala S. Sridhar, Begoña P. Valderrama, et al.. (2023). 2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC). Annals of Oncology. 34. S1209–S1210. 2 indexed citations

Jain, Rohit, Yuanquan Yang, Erika F.H. Saunders, et al.. (2023). 662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma. SHILAP Revista de lepidopterología. A754–A754. 2 indexed citations

Jenkins, Samir V., Shruti Shah, Azemat Jamshidi‐Parsian, et al.. (2023). Abstract 1088: Acquired radiation resistance induces thiol-dependent cisplatin cross-resistance. Cancer Research. 83(7_Supplement). 1088–1088. 1 indexed citations

Hu, Junxiao, Katharine A. Collier, Rana R. McKay, et al.. (2023). Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clinical Genitourinary Cancer. 21(4). 483–490. 7 indexed citations

Chitnis, Saurabh Deepak & Amir Mortazavi. (2023). Clinical guideline highlights for the hospitalist: Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy. Journal of Hospital Medicine. 18(11). 1013–1016. 6 indexed citations

10.

McLaughlin, Eric, et al.. (2023). Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience . Cancer Management and Research. Volume 15. 1245–1250. 4 indexed citations

11.

Welling, D. Bradley, Katharine A. Collier, Sarah S. Burns, et al.. (2021). Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology. 6(5). 1008–1019. 24 indexed citations

12.

Collier, Katharine A., Herbert B. Newton, Erinn M. Hade, et al.. (2021). A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 87(5). 599–611. 20 indexed citations

13.

Kaliński, Paweł, Claire F. Verschraegen, Steven K. Clinton, et al.. (2020). 156P High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma. Annals of Oncology. 31. S301–S301.

14.

Bekaii‐Saab, Tanios, Robert Wesolowski, Daniel H. Ahn, et al.. (2019). Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clinical Cancer Research. 25(12). 3495–3507. 54 indexed citations

15.

Duggan, Megan, et al.. (2019). The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy. Bladder Cancer. 5(2). 103–114. 3 indexed citations

16.

Grivas, Petros, Amir Mortazavi, Joel Picus, et al.. (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 125(4). 533–540. 36 indexed citations

17.

Harrison, Michael R., Peter H. O’Donnell, Ajjai Alva, et al.. (2017). Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC). Annals of Oncology. 28. v303–v304. 2 indexed citations

18.

Nadal, Rosa, Amir Mortazavi, Mark N. Stein, et al.. (2017). Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Annals of Oncology. 28. v295–v295. 19 indexed citations

19.

Riedl, Kenneth M., Robin A. Ralston, Jennifer M. Thomas‐Ahner, et al.. (2012). Inhibition of bladder cancer by broccoli isothiocyanates sulforaphane and erucin: Characterization, metabolism, and interconversion. Molecular Nutrition & Food Research. 56(11). 1675–1687. 82 indexed citations

20.

Shaukat, Aasma, Amir Mortazavi, Todd L. Demmy, et al.. (2004). Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?. Diseases of the Esophagus. 17(2). 129–135. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact